|October 25, 2013|
|07:44 EDT||MCK||McKesson price target raised to $191 from $150 at RW Baird|
Baird raised its price target on McKesson following its announced acquisition of Celesio. The firm would be aggressive buyers as the deal makes sense, is highly accretive, and its current below historic valuation. Shares are Outperform rated.
News For MCK From The Last 14 Days
|November 24, 2014|
|08:31 EDT||MCK||Omnicare, McKesson expand distribution agreement|
Omnicare (OCR) and McKesson Corporation (MCK) announced the signing of an expanded agreement to include the sourcing and distribution of branded, specialty and generic pharmaceuticals. The new five year agreement, which extends through December 2019, creates efficiencies for both companies by leveraging the strength of Omnicare as the nationís largest institutional pharmacy and a leading specialty pharmaceutical services provider and McKesson as a global leader in pharmaceutical sourcing and supply chain management. Omnicare noted that it believes the benefits of its new sourcing strategy will be a key driver in enabling it to generate a low double-digit adjusted cash EPS growth rate in 2015.
|07:33 EDT||MCK||Brean Capital to hold a summit|
Subscribe for More Information
|November 17, 2014|
|07:00 EDT||MCK||NovaBay signs distribution agreement with McKesson |
NovaBay (NBY) has signed a nationwide distribution agreement with McKesson Corporation (MCK). The agreement covers NovaBayís i-LidTM Cleanser, a prescription lid and lash hygiene product for the management of debilitating eye conditions such as blepharitis, Meibomian gland dysfunction and associated dry eye.
|November 14, 2014|
|07:14 EDT||MCK||American College of Rheumatology is holding a meeting|
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.